SB220025

SB220025 is a synthetic small molecule that acts as a potent, selective, and reversible ATP-competitive inhibitor of human p38 mitogen-activated protein kinase (MAPK), particularly the alpha isoform (MAPK14). It exhibits an IC50 of approximately 60 nM and demonstrates high selectivity—being 50 to over 2000-fold more selective for p38 MAPK compared to other kinases such as ERK, PKA, PKC, and EGFR. SB220025 inhibits angiogenesis and inflammatory cytokine production (notably TNF-alpha), making it useful in research on inflammation and chronic proliferative diseases. It has been shown to prevent progression in models of arthritis by reducing cytokine expression and angiogenesis. The compound was originally developed by Smithkline Beecham for experimental use; it is not approved for clinical use but is widely used as a tool compound in drug discovery[1][2][3][7][8].

Other names

5-(2-Amino-4-pyrimidinyl)-4-(4-fluorophenyl)-1-(4-piperidinlyl)imidazolep38 MAP Kinase Inhibitor XIVp-38 MAP Kinase Inhibitor XIVp 38 MAP Kinase Inhibitor XIV